Vicarious Surgical Inc. has announced its financial results for the first quarter of 2025, ending March 31. The company, which is advancing its single-port surgical system, reported operating expenses of $15.7 million, representing a 2% decrease from $16.1 million in the same period of the previous year. Research and development expenses were $9.4 million, down from $10.0 million in the first quarter of 2024. General and administrative expenses increased to $5.3 million from $5.0 million, while sales and marketing expenses slightly decreased to $1.0 million from $1.1 million in the prior year. The adjusted net loss for the quarter was $15.3 million, compared to a net loss of $15.1 million in the same period last year. The GAAP net loss for the first quarter was $15.4 million, an improvement from a net loss of $17.0 million in the previous year. As of March 31, 2025, the company had $37.4 million in cash and investments, with a cash burn rate of $11.7 million for the quarter. Vicarious Surgical projects a full-year 2025 cash burn of approximately $50 million. In operational updates, the company is on track to become a clinical-stage entity in 2025, marking a significant milestone with its first clinical patients anticipated within a few quarters. This is part of its ongoing efforts to demonstrate the value of its surgical system.